Johnson & Johnson news

   Watch this stock
Showing stories 1 - 10 of about 76   

Articles published

JNJ 95.50 -0.51 (-0.53%)
price chart
Johnson & Johnson facing massive class action
Medical giant Johnson & Johnson is facing its third class action in Australia in as many years, with a case filed in the Federal Court yesterday which relates to a product called transvaginal mesh.
Johnson & Johnson Agrees to Settle Five Rispersal Suits
Oct. 4 (Bloomberg) -- Johnson & Johnson agreed to settle five lawsuits over claims that its antipsychotic drug Risperdal caused increased breast-tissue growth in boys.
J.&J.'s Costs Take a Toll on Its Profit
Johnson & Johnson, the giant health care products maker, reported Tuesday that its third-quarter profit fell 7 percent as litigation and acquisition costs and factory upgrade expenses offset higher medicine and medical device sales.
Johnson & Johnson Tops Street in 3Q, Lifts Outlook  Fox Business
Johnson & Johnson Tops Forecasts on Lower Profit
Johnson & Johnson diabetes drug effective in high risk patients
An experimental treatment for type 2 diabetes developed by Johnson & Johnson proved effective at reducing blood sugar in patients on long-term insulin therapy and at high risk for heart problems, according to a study presented on Tuesday.
Tylenol and the Legacy of J&J's James Burke
This post is in partnership with Knowledge@Wharton, the online research and business analysis journal of the Wharton School of the University of Pennsylvania.
J&J's Global Creative Review Nears Finish
Johnson & Johnson is close to concluding its global review of creative responsibilities for its over-the-counter brands and sources expect the bulk of the business to be consolidated at three roster shops: DDB, BBDO and JWT.
Johnson & Johnson
Senior forward Samantha Johnson recorded the fastest goal in the history of USC's women's soccer program, scoring just 14 seconds into a game last fall against Washington State.
Done with Creative Review, J&J Turns Sights to Global Media Review
Johnson & Johnson has concluded its global creative agency review and is preparing to launch a global media review in markets not already in review, including North America, company executives said today.
Gores Group to Buy Johnson & Johnson Unit
The Gores Group on Monday said that it has agreed to acquire the maker of a medical device that's used to treat blood cancer from a unit of New Jersey health care conglomerate Johnson & Johnson. Therakos is a 25-year-old company based in Raritan, N.J ...
Gores Group to buy Therakos from Ortho-Clinical Diagnostics
Five reasons to like Johnson & Johnson
Johnson & Johnson has made headlines over the past couple of years - for all the wrong reasons. Plagued by quality control problems and costly product recalls affecting key brands such as Tylenol, Benadryl and Motrin, the health care giant's reputation ...